carboplatin + exemestane + pemetrexed

This combination involves **carboplatin**, a platinum-based chemotherapy drug; **exemestane**, an aromatase inhibitor used primarily in the treatment of breast cancer; and **pemetrexed**, an antifolate drug used in the treatment of non-small cell lung cancer and mesothelioma. The combination is being studied for its efficacy in treating postmenopausal non-small cell lung cancer (NSCLC) patients. Carboplatin and pemetrexed are commonly used together for NSCLC due to their effectiveness and lower toxicity compared to other platinum-based therapies. Exemestane's inclusion may target hormone-sensitive aspects of cancer. **Mechanism of Action:** - **Carboplatin** works by forming platinum-DNA adducts, which interfere with DNA repair mechanisms, leading to cell death. - **Exemestane** inhibits aromatase, an enzyme involved in estrogen synthesis, thereby reducing estrogen levels and slowing the growth of estrogen-dependent tumors. - **Pemetrexed** inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting DNA synthesis and repair in cancer cells.